Shonan iPark 2025: A Decade of Integrating Isotopic Labelling and Human ADME Studies to Streamline Drug Development Processes
7 October 2025
Overview
In the last 10 years over 500 radiolabelled molecules have been synthesised either as a standalone service through Arcinova or included as part of a fully integrated human ADME programme through the Synthesis-to-Clinic® offering by Quotient Sciences
Adopting a Synthesis-to-Clinic® approach offers significant advantages including accelerated timelines, reduced risk, and cost efficiencies.
Download the poster to discover:
- How our experts label APIs at the optimal position
- How a human ADME study is designed
- Key applications of human ADME and IVMT/ADME studies